Table of Content

1 Novel Coronavirus Inactivated Vaccine Market Overview
1.1 Product Overview and Scope of Novel Coronavirus Inactivated Vaccine
1.2 Novel Coronavirus Inactivated Vaccine Segment by Type
1.2.1 Global Novel Coronavirus Inactivated Vaccine Market Value Comparison by Type (2024-2034)
1.2.2 Adult
1.2.3 Child
1.3 Novel Coronavirus Inactivated Vaccine Segment by Application
1.3.1 Global Novel Coronavirus Inactivated Vaccine Market Value by Application: (2024-2034)
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Novel Coronavirus Inactivated Vaccine Market Size Estimates and Forecasts
1.4.1 Global Novel Coronavirus Inactivated Vaccine Revenue 2024-2034
1.4.2 Global Novel Coronavirus Inactivated Vaccine Sales 2024-2034
1.4.3 Global Novel Coronavirus Inactivated Vaccine Market Average Price (2024-2034)
1.5 Assumptions and Limitations
2 Novel Coronavirus Inactivated Vaccine Market Competition by Manufacturers
2.1 Global Novel Coronavirus Inactivated Vaccine Sales Market Share by Manufacturers (2024-2024)
2.2 Global Novel Coronavirus Inactivated Vaccine Revenue Market Share by Manufacturers (2024-2024)
2.3 Global Novel Coronavirus Inactivated Vaccine Average Price by Manufacturers (2024-2024)
2.4 Global Novel Coronavirus Inactivated Vaccine Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of Novel Coronavirus Inactivated Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Novel Coronavirus Inactivated Vaccine, Product Type & Application
2.7 Novel Coronavirus Inactivated Vaccine Market Competitive Situation and Trends
2.7.1 Novel Coronavirus Inactivated Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Novel Coronavirus Inactivated Vaccine Players Market Share by Revenue
2.7.3 Global Novel Coronavirus Inactivated Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Novel Coronavirus Inactivated Vaccine Retrospective Market Scenario by Region
3.1 Global Novel Coronavirus Inactivated Vaccine Market Size by Region: 2024 Versus 2022 Versus 2034
3.2 Global Novel Coronavirus Inactivated Vaccine Global Novel Coronavirus Inactivated Vaccine Sales by Region: 2024-2034
3.2.1 Global Novel Coronavirus Inactivated Vaccine Sales by Region: 2024-2024
3.2.2 Global Novel Coronavirus Inactivated Vaccine Sales by Region: 2024-2034
3.3 Global Novel Coronavirus Inactivated Vaccine Global Novel Coronavirus Inactivated Vaccine Revenue by Region: 2024-2034
3.3.1 Global Novel Coronavirus Inactivated Vaccine Revenue by Region: 2024-2024
3.3.2 Global Novel Coronavirus Inactivated Vaccine Revenue by Region: 2024-2034
3.4 North America Novel Coronavirus Inactivated Vaccine Market Facts & Figures by Country
3.4.1 North America Novel Coronavirus Inactivated Vaccine Market Size by Country: 2024 VS 2022 VS 2034
3.4.2 North America Novel Coronavirus Inactivated Vaccine Sales by Country (2024-2034)
3.4.3 North America Novel Coronavirus Inactivated Vaccine Revenue by Country (2024-2034)
3.4.4 United States
3.4.5 Canada
3.5 Europe Novel Coronavirus Inactivated Vaccine Market Facts & Figures by Country
3.5.1 Europe Novel Coronavirus Inactivated Vaccine Market Size by Country: 2024 VS 2022 VS 2034
3.5.2 Europe Novel Coronavirus Inactivated Vaccine Sales by Country (2024-2034)
3.5.3 Europe Novel Coronavirus Inactivated Vaccine Revenue by Country (2024-2034)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Novel Coronavirus Inactivated Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Novel Coronavirus Inactivated Vaccine Market Size by Country: 2024 VS 2022 VS 2034
3.6.2 Asia Pacific Novel Coronavirus Inactivated Vaccine Sales by Country (2024-2034)
3.6.3 Asia Pacific Novel Coronavirus Inactivated Vaccine Revenue by Country (2024-2034)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Novel Coronavirus Inactivated Vaccine Market Facts & Figures by Country
3.7.1 Latin America Novel Coronavirus Inactivated Vaccine Market Size by Country: 2024 VS 2022 VS 2034
3.7.2 Latin America Novel Coronavirus Inactivated Vaccine Sales by Country (2024-2034)
3.7.3 Latin America Novel Coronavirus Inactivated Vaccine Revenue by Country (2024-2034)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Novel Coronavirus Inactivated Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Novel Coronavirus Inactivated Vaccine Market Size by Country: 2024 VS 2022 VS 2034
3.8.2 Middle East and Africa Novel Coronavirus Inactivated Vaccine Sales by Country (2024-2034)
3.8.3 Middle East and Africa Novel Coronavirus Inactivated Vaccine Revenue by Country (2024-2034)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Novel Coronavirus Inactivated Vaccine Sales by Type (2024-2034)
4.1.1 Global Novel Coronavirus Inactivated Vaccine Sales by Type (2024-2024)
4.1.2 Global Novel Coronavirus Inactivated Vaccine Sales by Type (2024-2034)
4.1.3 Global Novel Coronavirus Inactivated Vaccine Sales Market Share by Type (2024-2034)
4.2 Global Novel Coronavirus Inactivated Vaccine Revenue by Type (2024-2034)
4.2.1 Global Novel Coronavirus Inactivated Vaccine Revenue by Type (2024-2024)
4.2.2 Global Novel Coronavirus Inactivated Vaccine Revenue by Type (2024-2034)
4.2.3 Global Novel Coronavirus Inactivated Vaccine Revenue Market Share by Type (2024-2034)
4.3 Global Novel Coronavirus Inactivated Vaccine Price by Type (2024-2034)
5 Segment by Application
5.1 Global Novel Coronavirus Inactivated Vaccine Sales by Application (2024-2034)
5.1.1 Global Novel Coronavirus Inactivated Vaccine Sales by Application (2024-2024)
5.1.2 Global Novel Coronavirus Inactivated Vaccine Sales by Application (2024-2034)
5.1.3 Global Novel Coronavirus Inactivated Vaccine Sales Market Share by Application (2024-2034)
5.2 Global Novel Coronavirus Inactivated Vaccine Revenue by Application (2024-2034)
5.2.1 Global Novel Coronavirus Inactivated Vaccine Revenue by Application (2024-2024)
5.2.2 Global Novel Coronavirus Inactivated Vaccine Revenue by Application (2024-2034)
5.2.3 Global Novel Coronavirus Inactivated Vaccine Revenue Market Share by Application (2024-2034)
5.3 Global Novel Coronavirus Inactivated Vaccine Price by Application (2024-2034)
6 Key Companies Profiled
6.1 Inovio Pharmaceuticals
6.1.1 Inovio Pharmaceuticals Corporation Information
6.1.2 Inovio Pharmaceuticals Description and Business Overview
6.1.3 Inovio Pharmaceuticals Novel Coronavirus Inactivated Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.1.4 Inovio Pharmaceuticals Novel Coronavirus Inactivated Vaccine Product Portfolio
6.1.5 Inovio Pharmaceuticals Recent Developments/Updates
6.2 Moderna
6.2.1 Moderna Corporation Information
6.2.2 Moderna Description and Business Overview
6.2.3 Moderna Novel Coronavirus Inactivated Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.2.4 Moderna Novel Coronavirus Inactivated Vaccine Product Portfolio
6.2.5 Moderna Recent Developments/Updates
6.3 GlaxoSmithKine
6.3.1 GlaxoSmithKine Corporation Information
6.3.2 GlaxoSmithKine Description and Business Overview
6.3.3 GlaxoSmithKine Novel Coronavirus Inactivated Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.3.4 GlaxoSmithKine Novel Coronavirus Inactivated Vaccine Product Portfolio
6.3.5 GlaxoSmithKine Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Corporation Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Novel Coronavirus Inactivated Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.4.4 Pfizer Novel Coronavirus Inactivated Vaccine Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Johnson&Johnson
6.5.1 Johnson&Johnson Corporation Information
6.5.2 Johnson&Johnson Description and Business Overview
6.5.3 Johnson&Johnson Novel Coronavirus Inactivated Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.5.4 Johnson&Johnson Novel Coronavirus Inactivated Vaccine Product Portfolio
6.5.5 Johnson&Johnson Recent Developments/Updates
6.6 Heat Biologics
6.6.1 Heat Biologics Corporation Information
6.6.2 Heat Biologics Description and Business Overview
6.6.3 Heat Biologics Novel Coronavirus Inactivated Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.6.4 Heat Biologics Novel Coronavirus Inactivated Vaccine Product Portfolio
6.6.5 Heat Biologics Recent Developments/Updates
6.7 Sanofi
6.6.1 Sanofi Corporation Information
6.6.2 Sanofi Description and Business Overview
6.6.3 Sanofi Novel Coronavirus Inactivated Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.4.4 Sanofi Novel Coronavirus Inactivated Vaccine Product Portfolio
6.7.5 Sanofi Recent Developments/Updates
6.8 Beijing Institute of Biological Products Co., Ltd
6.8.1 Beijing Institute of Biological Products Co., Ltd Corporation Information
6.8.2 Beijing Institute of Biological Products Co., Ltd Description and Business Overview
6.8.3 Beijing Institute of Biological Products Co., Ltd Novel Coronavirus Inactivated Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.8.4 Beijing Institute of Biological Products Co., Ltd Novel Coronavirus Inactivated Vaccine Product Portfolio
6.8.5 Beijing Institute of Biological Products Co., Ltd Recent Developments/Updates
6.9 Beijing Kexing Zhongwei Biotechnology Co., Ltd
6.9.1 Beijing Kexing Zhongwei Biotechnology Co., Ltd Corporation Information
6.9.2 Beijing Kexing Zhongwei Biotechnology Co., Ltd Description and Business Overview
6.9.3 Beijing Kexing Zhongwei Biotechnology Co., Ltd Novel Coronavirus Inactivated Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.9.4 Beijing Kexing Zhongwei Biotechnology Co., Ltd Novel Coronavirus Inactivated Vaccine Product Portfolio
6.9.5 Beijing Kexing Zhongwei Biotechnology Co., Ltd Recent Developments/Updates
6.10 Shanghai Pharmaceutical CanSino Biopharmaceutical Co., Ltd
6.10.1 Shanghai Pharmaceutical CanSino Biopharmaceutical Co., Ltd Corporation Information
6.10.2 Shanghai Pharmaceutical CanSino Biopharmaceutical Co., Ltd Description and Business Overview
6.10.3 Shanghai Pharmaceutical CanSino Biopharmaceutical Co., Ltd Novel Coronavirus Inactivated Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.10.4 Shanghai Pharmaceutical CanSino Biopharmaceutical Co., Ltd Novel Coronavirus Inactivated Vaccine Product Portfolio
6.10.5 Shanghai Pharmaceutical CanSino Biopharmaceutical Co., Ltd Recent Developments/Updates
6.11 Wuhan Institute of Biological Products Co., Ltd
6.11.1 Wuhan Institute of Biological Products Co., Ltd Corporation Information
6.11.2 Wuhan Institute of Biological Products Co., Ltd Novel Coronavirus Inactivated Vaccine Description and Business Overview
6.11.3 Wuhan Institute of Biological Products Co., Ltd Novel Coronavirus Inactivated Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.11.4 Wuhan Institute of Biological Products Co., Ltd Novel Coronavirus Inactivated Vaccine Product Portfolio
6.11.5 Wuhan Institute of Biological Products Co., Ltd Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Novel Coronavirus Inactivated Vaccine Industry Chain Analysis
7.2 Novel Coronavirus Inactivated Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Novel Coronavirus Inactivated Vaccine Production Mode & Process
7.4 Novel Coronavirus Inactivated Vaccine Sales and Marketing
7.4.1 Novel Coronavirus Inactivated Vaccine Sales Channels
7.4.2 Novel Coronavirus Inactivated Vaccine Distributors
7.5 Novel Coronavirus Inactivated Vaccine Customers
8 Novel Coronavirus Inactivated Vaccine Market Dynamics
8.1 Novel Coronavirus Inactivated Vaccine Industry Trends
8.2 Novel Coronavirus Inactivated Vaccine Market Drivers
8.3 Novel Coronavirus Inactivated Vaccine Market Challenges
8.4 Novel Coronavirus Inactivated Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Novel Coronavirus Inactivated Vaccine Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Novel Coronavirus Inactivated Vaccine Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Novel Coronavirus Inactivated Vaccine Market Competitive Situation by Manufacturers in 2022
Table 4. Global Novel Coronavirus Inactivated Vaccine Sales (K Units) of Key Manufacturers (2024-2024)
Table 5. Global Novel Coronavirus Inactivated Vaccine Sales Market Share by Manufacturers (2024-2024)
Table 6. Global Novel Coronavirus Inactivated Vaccine Revenue (US$ Million) by Manufacturers (2024-2024)
Table 7. Global Novel Coronavirus Inactivated Vaccine Revenue Share by Manufacturers (2024-2024)
Table 8. Global Market Novel Coronavirus Inactivated Vaccine Average Price (US$/Unit) of Key Manufacturers (2024-2024)
Table 9. Global Key Players of Novel Coronavirus Inactivated Vaccine, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of Novel Coronavirus Inactivated Vaccine, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Novel Coronavirus Inactivated Vaccine, Product Type & Application
Table 12. Global Key Manufacturers of Novel Coronavirus Inactivated Vaccine, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Novel Coronavirus Inactivated Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Novel Coronavirus Inactivated Vaccine as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Novel Coronavirus Inactivated Vaccine Market Size by Region (US$ Million): 2024 VS 2022 VS 2034
Table 17. Global Novel Coronavirus Inactivated Vaccine Sales by Region (2024-2024) & (K Units)
Table 18. Global Novel Coronavirus Inactivated Vaccine Sales Market Share by Region (2024-2024)
Table 19. Global Novel Coronavirus Inactivated Vaccine Sales by Region (2024-2034) & (K Units)
Table 20. Global Novel Coronavirus Inactivated Vaccine Sales Market Share by Region (2024-2034)
Table 21. Global Novel Coronavirus Inactivated Vaccine Revenue by Region (2024-2024) & (US$ Million)
Table 22. Global Novel Coronavirus Inactivated Vaccine Revenue Market Share by Region (2024-2024)
Table 23. Global Novel Coronavirus Inactivated Vaccine Revenue by Region (2024-2034) & (US$ Million)
Table 24. Global Novel Coronavirus Inactivated Vaccine Revenue Market Share by Region (2024-2034)
Table 25. North America Novel Coronavirus Inactivated Vaccine Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 26. North America Novel Coronavirus Inactivated Vaccine Sales by Country (2024-2024) & (K Units)
Table 27. North America Novel Coronavirus Inactivated Vaccine Sales by Country (2024-2034) & (K Units)
Table 28. North America Novel Coronavirus Inactivated Vaccine Revenue by Country (2024-2024) & (US$ Million)
Table 29. North America Novel Coronavirus Inactivated Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 30. Europe Novel Coronavirus Inactivated Vaccine Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 31. Europe Novel Coronavirus Inactivated Vaccine Sales by Country (2024-2024) & (K Units)
Table 32. Europe Novel Coronavirus Inactivated Vaccine Sales by Country (2024-2034) & (K Units)
Table 33. Europe Novel Coronavirus Inactivated Vaccine Revenue by Country (2024-2024) & (US$ Million)
Table 34. Europe Novel Coronavirus Inactivated Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 35. Asia Pacific Novel Coronavirus Inactivated Vaccine Revenue by Region: 2024 VS 2022 VS 2034 (US$ Million)
Table 36. Asia Pacific Novel Coronavirus Inactivated Vaccine Sales by Region (2024-2024) & (K Units)
Table 37. Asia Pacific Novel Coronavirus Inactivated Vaccine Sales by Region (2024-2034) & (K Units)
Table 38. Asia Pacific Novel Coronavirus Inactivated Vaccine Revenue by Region (2024-2024) & (US$ Million)
Table 39. Asia Pacific Novel Coronavirus Inactivated Vaccine Revenue by Region (2024-2034) & (US$ Million)
Table 40. Latin America Novel Coronavirus Inactivated Vaccine Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 41. Latin America Novel Coronavirus Inactivated Vaccine Sales by Country (2024-2024) & (K Units)
Table 42. Latin America Novel Coronavirus Inactivated Vaccine Sales by Country (2024-2034) & (K Units)
Table 43. Latin America Novel Coronavirus Inactivated Vaccine Revenue by Country (2024-2024) & (US$ Million)
Table 44. Latin America Novel Coronavirus Inactivated Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 45. Middle East & Africa Novel Coronavirus Inactivated Vaccine Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 46. Middle East & Africa Novel Coronavirus Inactivated Vaccine Sales by Country (2024-2024) & (K Units)
Table 47. Middle East & Africa Novel Coronavirus Inactivated Vaccine Sales by Country (2024-2034) & (K Units)
Table 48. Middle East & Africa Novel Coronavirus Inactivated Vaccine Revenue by Country (2024-2024) & (US$ Million)
Table 49. Middle East & Africa Novel Coronavirus Inactivated Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 50. Global Novel Coronavirus Inactivated Vaccine Sales (K Units) by Type (2024-2024)
Table 51. Global Novel Coronavirus Inactivated Vaccine Sales (K Units) by Type (2024-2034)
Table 52. Global Novel Coronavirus Inactivated Vaccine Sales Market Share by Type (2024-2024)
Table 53. Global Novel Coronavirus Inactivated Vaccine Sales Market Share by Type (2024-2034)
Table 54. Global Novel Coronavirus Inactivated Vaccine Revenue (US$ Million) by Type (2024-2024)
Table 55. Global Novel Coronavirus Inactivated Vaccine Revenue (US$ Million) by Type (2024-2034)
Table 56. Global Novel Coronavirus Inactivated Vaccine Revenue Market Share by Type (2024-2024)
Table 57. Global Novel Coronavirus Inactivated Vaccine Revenue Market Share by Type (2024-2034)
Table 58. Global Novel Coronavirus Inactivated Vaccine Price (US$/Unit) by Type (2024-2024)
Table 59. Global Novel Coronavirus Inactivated Vaccine Price (US$/Unit) by Type (2024-2034)
Table 60. Global Novel Coronavirus Inactivated Vaccine Sales (K Units) by Application (2024-2024)
Table 61. Global Novel Coronavirus Inactivated Vaccine Sales (K Units) by Application (2024-2034)
Table 62. Global Novel Coronavirus Inactivated Vaccine Sales Market Share by Application (2024-2024)
Table 63. Global Novel Coronavirus Inactivated Vaccine Sales Market Share by Application (2024-2034)
Table 64. Global Novel Coronavirus Inactivated Vaccine Revenue (US$ Million) by Application (2024-2024)
Table 65. Global Novel Coronavirus Inactivated Vaccine Revenue (US$ Million) by Application (2024-2034)
Table 66. Global Novel Coronavirus Inactivated Vaccine Revenue Market Share by Application (2024-2024)
Table 67. Global Novel Coronavirus Inactivated Vaccine Revenue Market Share by Application (2024-2034)
Table 68. Global Novel Coronavirus Inactivated Vaccine Price (US$/Unit) by Application (2024-2024)
Table 69. Global Novel Coronavirus Inactivated Vaccine Price (US$/Unit) by Application (2024-2034)
Table 70. Inovio Pharmaceuticals Corporation Information
Table 71. Inovio Pharmaceuticals Description and Business Overview
Table 72. Inovio Pharmaceuticals Novel Coronavirus Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 73. Inovio Pharmaceuticals Novel Coronavirus Inactivated Vaccine Product
Table 74. Inovio Pharmaceuticals Recent Developments/Updates
Table 75. Moderna Corporation Information
Table 76. Moderna Description and Business Overview
Table 77. Moderna Novel Coronavirus Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 78. Moderna Novel Coronavirus Inactivated Vaccine Product
Table 79. Moderna Recent Developments/Updates
Table 80. GlaxoSmithKine Corporation Information
Table 81. GlaxoSmithKine Description and Business Overview
Table 82. GlaxoSmithKine Novel Coronavirus Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 83. GlaxoSmithKine Novel Coronavirus Inactivated Vaccine Product
Table 84. GlaxoSmithKine Recent Developments/Updates
Table 85. Pfizer Corporation Information
Table 86. Pfizer Description and Business Overview
Table 87. Pfizer Novel Coronavirus Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 88. Pfizer Novel Coronavirus Inactivated Vaccine Product
Table 89. Pfizer Recent Developments/Updates
Table 90. Johnson&Johnson Corporation Information
Table 91. Johnson&Johnson Description and Business Overview
Table 92. Johnson&Johnson Novel Coronavirus Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 93. Johnson&Johnson Novel Coronavirus Inactivated Vaccine Product
Table 94. Johnson&Johnson Recent Developments/Updates
Table 95. Heat Biologics Corporation Information
Table 96. Heat Biologics Description and Business Overview
Table 97. Heat Biologics Novel Coronavirus Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 98. Heat Biologics Novel Coronavirus Inactivated Vaccine Product
Table 99. Heat Biologics Recent Developments/Updates
Table 100. Sanofi Corporation Information
Table 101. Sanofi Description and Business Overview
Table 102. Sanofi Novel Coronavirus Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 103. Sanofi Novel Coronavirus Inactivated Vaccine Product
Table 104. Sanofi Recent Developments/Updates
Table 105. Beijing Institute of Biological Products Co., Ltd Corporation Information
Table 106. Beijing Institute of Biological Products Co., Ltd Description and Business Overview
Table 107. Beijing Institute of Biological Products Co., Ltd Novel Coronavirus Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 108. Beijing Institute of Biological Products Co., Ltd Novel Coronavirus Inactivated Vaccine Product
Table 109. Beijing Institute of Biological Products Co., Ltd Recent Developments/Updates
Table 110. Beijing Kexing Zhongwei Biotechnology Co., Ltd Corporation Information
Table 111. Beijing Kexing Zhongwei Biotechnology Co., Ltd Description and Business Overview
Table 112. Beijing Kexing Zhongwei Biotechnology Co., Ltd Novel Coronavirus Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 113. Beijing Kexing Zhongwei Biotechnology Co., Ltd Novel Coronavirus Inactivated Vaccine Product
Table 114. Beijing Kexing Zhongwei Biotechnology Co., Ltd Recent Developments/Updates
Table 115. Shanghai Pharmaceutical CanSino Biopharmaceutical Co., Ltd Corporation Information
Table 116. Shanghai Pharmaceutical CanSino Biopharmaceutical Co., Ltd Description and Business Overview
Table 117. Shanghai Pharmaceutical CanSino Biopharmaceutical Co., Ltd Novel Coronavirus Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 118. Shanghai Pharmaceutical CanSino Biopharmaceutical Co., Ltd Novel Coronavirus Inactivated Vaccine Product
Table 119. Shanghai Pharmaceutical CanSino Biopharmaceutical Co., Ltd Recent Developments/Updates
Table 120. Wuhan Institute of Biological Products Co., Ltd Corporation Information
Table 121. Wuhan Institute of Biological Products Co., Ltd Description and Business Overview
Table 122. Wuhan Institute of Biological Products Co., Ltd Novel Coronavirus Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 123. Wuhan Institute of Biological Products Co., Ltd Novel Coronavirus Inactivated Vaccine Product
Table 124. Wuhan Institute of Biological Products Co., Ltd Recent Developments/Updates
Table 125. Key Raw Materials Lists
Table 126. Raw Materials Key Suppliers Lists
Table 127. Novel Coronavirus Inactivated Vaccine Distributors List
Table 128. Novel Coronavirus Inactivated Vaccine Customers List
Table 129. Novel Coronavirus Inactivated Vaccine Market Trends
Table 130. Novel Coronavirus Inactivated Vaccine Market Drivers
Table 131. Novel Coronavirus Inactivated Vaccine Market Challenges
Table 132. Novel Coronavirus Inactivated Vaccine Market Restraints
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Novel Coronavirus Inactivated Vaccine
Figure 2. Global Novel Coronavirus Inactivated Vaccine Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Novel Coronavirus Inactivated Vaccine Market Share by Type in 2022 & 2034
Figure 4. Adult Product Picture
Figure 5. Child Product Picture
Figure 6. Global Novel Coronavirus Inactivated Vaccine Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 7. Global Novel Coronavirus Inactivated Vaccine Market Share by Application in 2022 & 2034
Figure 8. Hospital
Figure 9. Clinic
Figure 10. Global Novel Coronavirus Inactivated Vaccine Revenue, (US$ Million), 2024 VS 2022 VS 2034
Figure 11. Global Novel Coronavirus Inactivated Vaccine Market Size (2024-2034) & (US$ Million)
Figure 12. Global Novel Coronavirus Inactivated Vaccine Sales (2024-2034) & (K Units)
Figure 13. Global Novel Coronavirus Inactivated Vaccine Average Price (US$/Unit) & (2024-2034)
Figure 14. Novel Coronavirus Inactivated Vaccine Report Years Considered
Figure 15. Novel Coronavirus Inactivated Vaccine Sales Share by Manufacturers in 2022
Figure 16. Global Novel Coronavirus Inactivated Vaccine Revenue Share by Manufacturers in 2022
Figure 17. The Global 5 and 10 Largest Novel Coronavirus Inactivated Vaccine Players: Market Share by Revenue in 2022
Figure 18. Novel Coronavirus Inactivated Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024 VS 2022
Figure 19. Global Novel Coronavirus Inactivated Vaccine Market Size by Region (US$ Million): 2024 VS 2022 VS 2034
Figure 20. North America Novel Coronavirus Inactivated Vaccine Sales Market Share by Country (2024-2034)
Figure 21. North America Novel Coronavirus Inactivated Vaccine Revenue Market Share by Country (2024-2034)
Figure 22. United States Novel Coronavirus Inactivated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 23. Canada Novel Coronavirus Inactivated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 24. Europe Novel Coronavirus Inactivated Vaccine Sales Market Share by Country (2024-2034)
Figure 25. Europe Novel Coronavirus Inactivated Vaccine Revenue Market Share by Country (2024-2034)
Figure 26. Germany Novel Coronavirus Inactivated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 27. France Novel Coronavirus Inactivated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 28. U.K. Novel Coronavirus Inactivated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 29. Italy Novel Coronavirus Inactivated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 30. Russia Novel Coronavirus Inactivated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 31. Asia Pacific Novel Coronavirus Inactivated Vaccine Sales Market Share by Region (2024-2034)
Figure 32. Asia Pacific Novel Coronavirus Inactivated Vaccine Revenue Market Share by Region (2024-2034)
Figure 33. China Novel Coronavirus Inactivated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 34. Japan Novel Coronavirus Inactivated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 35. South Korea Novel Coronavirus Inactivated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 36. India Novel Coronavirus Inactivated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 37. Australia Novel Coronavirus Inactivated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 38. China Taiwan Novel Coronavirus Inactivated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 39. Southeast Asia Novel Coronavirus Inactivated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 40. Latin America Novel Coronavirus Inactivated Vaccine Sales Market Share by Country (2024-2034)
Figure 41. Latin America Novel Coronavirus Inactivated Vaccine Revenue Market Share by Country (2024-2034)
Figure 42. Mexico Novel Coronavirus Inactivated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 43. Brazil Novel Coronavirus Inactivated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 44. Argentina Novel Coronavirus Inactivated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 45. Middle East & Africa Novel Coronavirus Inactivated Vaccine Sales Market Share by Country (2024-2034)
Figure 46. Middle East & Africa Novel Coronavirus Inactivated Vaccine Revenue Market Share by Country (2024-2034)
Figure 47. Turkey Novel Coronavirus Inactivated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 48. Saudi Arabia Novel Coronavirus Inactivated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 49. UAE Novel Coronavirus Inactivated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 50. Global Sales Market Share of Novel Coronavirus Inactivated Vaccine by Type (2024-2034)
Figure 51. Global Revenue Market Share of Novel Coronavirus Inactivated Vaccine by Type (2024-2034)
Figure 52. Global Novel Coronavirus Inactivated Vaccine Price (US$/Unit) by Type (2024-2034)
Figure 53. Global Sales Market Share of Novel Coronavirus Inactivated Vaccine by Application (2024-2034)
Figure 54. Global Revenue Market Share of Novel Coronavirus Inactivated Vaccine by Application (2024-2034)
Figure 55. Global Novel Coronavirus Inactivated Vaccine Price (US$/Unit) by Application (2024-2034)
Figure 56. Novel Coronavirus Inactivated Vaccine Value Chain
Figure 57. Novel Coronavirus Inactivated Vaccine Production Process
Figure 58. Channels of Distribution (Direct Vs Distribution)
Figure 59. Distributors Profiles
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed